PMID- 25110835
OWN - NLM
STAT- MEDLINE
DCOM- 20160201
LR  - 20220317
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Linking)
VI  - 54
IP  - 11
DP  - 2015 Nov
TI  - Expression quantitative trait loci in long non-coding RNA ZNRD1-AS1 influence 
      both HBV infection and hepatocellular carcinoma development.
PG  - 1275-82
LID - 10.1002/mc.22200 [doi]
AB  - Zinc ribbon domain containing 1 (ZNRD1), cloned from human leukocyte antigen 
      (HLA) region, may play integral roles in diverse processes including immune 
      response against HBV infection and hepatocarcinogenesis. ZNRD1-AS1 (ZNRD1 
      antisense RNA 1) may be an important regulator of ZNRD1. By bioinformatics 
      analyses, we identified that several single nucleotide polymorphisms (SNPs) in 
      ZNRD1-AS1 may be expression quantitative trait loci (eQTLs) for ZNRD1. In this 
      study, we hypothesized that these eQTLs SNPs in ZNRD1-AS1 may influence both 
      chronic HBV infection and hepatocellular carcinoma (HCC) development. We designed 
      a case-control study of 1300 HBV-positive HCC patients, 1344 HBV persistent 
      carriers and, 1344 HBV natural clearance subjects to test the associations of 
      three ZNRD1 eQTLs SNPs (rs3757328, rs6940552 and, rs9261204) in ZNRD1-AS1 with 
      the risk of both chronic HBV infection and HCC. Logistic regression analyses in 
      additive genetic model showed that variant alleles of all the three SNPs 
      increased host HCC risk, whereas variant allele of rs3757328 was associated with 
      HBV clearance. Moreover, the haplotype containing variant alleles of the three 
      SNPs was significantly associated with both HCC development (adjusted OR = 1.18, 
      95% CI = 1.01-1.38, P = 0.035) and HBV clearance (adjusted OR = 0.83, 95% 
      CI = 0.71-0.96, P = 0.013), when compared with the most frequent haplotype. In 
      vitro experiments showed that ZNRD1 knockdown inhibited the expression of HBV 
      mRNA and promoted proliferation of HepG2.2.15 cells. These findings suggest that 
      ZNRD1 regulatory SNPs may be susceptibility makers for risk of both chronic HBV 
      infection and HCC.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Wen, Juan
AU  - Wen J
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Liu, Yao
AU  - Liu Y
AD  - Pathology Center and Department of Pathology, Soochow University, Suzhou, China.
FAU - Liu, Jibin
AU  - Liu J
AD  - Department of Hepatobiliary Surgery, Nantong Tumor Hospital, Nantong, China.
FAU - Liu, Li
AU  - Liu L
AD  - Digestive Endoscopy Center, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Song, Ci
AU  - Song C
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Han, Jing
AU  - Han J
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Zhu, Liguo
AU  - Zhu L
AD  - Department of Infection Diseases, Jiangsu Province Center for Disease Prevention 
      and Control, Nanjing, China.
FAU - Wang, Cheng
AU  - Wang C
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Chen, Jianguo
AU  - Chen J
AD  - Qidong Liver Cancer Institute, Qidong, China.
FAU - Zhai, Xiangjun
AU  - Zhai X
AD  - Department of Infection Diseases, Jiangsu Province Center for Disease Prevention 
      and Control, Nanjing, China.
FAU - Shen, Hongbin
AU  - Shen H
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Hu, Zhibin
AU  - Hu Z
AD  - Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer 
      Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140811
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (POLR1H protein, human)
RN  - 0 (RNA, Antisense)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Alleles
MH  - Carcinoma, Hepatocellular/*genetics
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Hep G2 Cells
MH  - Hepatitis B virus/pathogenicity
MH  - Hepatitis B, Chronic/*genetics/virology
MH  - Humans
MH  - Liver Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Quantitative Trait Loci/*genetics
MH  - RNA, Antisense/*genetics
MH  - RNA, Long Noncoding/*genetics
MH  - RNA, Messenger/genetics
OTO - NOTNLM
OT  - HCC
OT  - ZNRD1
OT  - eQTLs
OT  - susceptibility
EDAT- 2014/08/12 06:00
MHDA- 2016/02/02 06:00
CRDT- 2014/08/12 06:00
PHST- 2014/02/19 00:00 [received]
PHST- 2014/06/05 00:00 [revised]
PHST- 2014/06/07 00:00 [accepted]
PHST- 2014/08/12 06:00 [entrez]
PHST- 2014/08/12 06:00 [pubmed]
PHST- 2016/02/02 06:00 [medline]
AID - 10.1002/mc.22200 [doi]
PST - ppublish
SO  - Mol Carcinog. 2015 Nov;54(11):1275-82. doi: 10.1002/mc.22200. Epub 2014 Aug 11.